Glucagon administration system and methods

• US 10,549,037 B2
• Filed: 03/17/2017
• Issued: 02/04/2020
• Est. Priority Date: 07/01/2014
• Status: Active Grant

• Current Assignee: Bigfoot Biomedical, Inc. (Abbott Laboratories)
• Original Assignee: Bigfoot Biomedical, Inc. (Abbott Laboratories)
• Inventors: Estes, Mark C.
• Primary Examiner(s): Schmidt, Emily L
• Application Number:
  US15/462,334
• Publication Number:
  US 20170189615A1
• Time in Patent Office: 1,054 Days
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61M 2202/0486 Glucose
• CPC Class Codes: A61M 2205/3561 local, e.g. within room or hospital
• CPC Class Codes: A61M 2205/3584 using modem, internet or bluetooth
• CPC Class Codes: A61M 2205/3592 using telemetric means, e.g. radio or optical transmission
• CPC Class Codes: A61M 2205/50 with microprocessors or computers
• CPC Class Codes: A61M 2205/502 User interfaces, e.g. screens or keyboards
• CPC Class Codes: A61M 2205/52 with memories providing a history of measured variating parameters of apparatus or patient
• CPC Class Codes: A61M 2205/8206 battery-operated
• CPC Class Codes: A61M 2230/201 Glucose concentration
• CPC Class Codes: A61M 5/003 Kits for diabetics
• CPC Class Codes: A61M 5/14244 adapted to be carried by the patient, e.g. portable on the body
• CPC Class Codes: A61M 5/14248 of the skin patch type
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: A61M 5/24 Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic ampoules or carpules A61J1/06
• CPC Class Codes: G16H 20/17 delivered via infusion or injection
• CPC Class Codes: G16H 40/67 for remote operation

Abstract

Some embodiments a glucagon administration system can provide a suggested glucagon dosage based on one or more particular parameters (e.g., the user'"'"'s recent blood glucose characteristics, a glucagon sensitivity value of the user, and other parameters). In some circumstances, the glucagon administration system can receive information indicative of the user'"'"'s blood glucose level and suggest a glucagon dosage that is at least partially dependent upon a previously stored glucagon sensitivity for the user.

Claims

1. A medicine administration system, comprising:

a wearable glucose monitoring device;

a disposable and non-reusable insulin delivery device including;

an insulin cartridge comprising a plunger, a septum, and insulin;

a housing that retains the insulin cartridge; and

a drive system comprising a piston rod that is incrementally movable to apply a dispensing force to the plunger to dispense insulin through the septum;

a removable controller device including;

a controller housing that is removably attachable to the housing of the insulin delivery device;

a user interface comprising a display and one or more user-selectable buttons; and

a wireless communication device to receive glucose information from the wearable glucose monitoring device, the glucose information being indicative of a blood glucose level of the user,

wherein the removable controller device displays a suggested glucagon dosage in response to user input to the system, the suggested glucagon dosage being at least partially dependent upon a glucose sensitivity value, a target blood glucose level, and the blood glucose level of the user; and

a glucagon injector pen device or syringe that is separate from the disposable and non-reusable insulin delivery device and the controller device.

2. The system of claim 1, wherein the controller device is configured to activate a glucagon dosage calculator that calculates the suggested glucagon dosage based at least in part on the glucose sensitivity value stored by the controller device, the target blood glucose level stored by the controller device, and the blood glucose level of the user.

3. The system of claim 1, wherein the glucagon injector pen device or syringe is a glucagon injector pen in wireless communication with the removable controller device.

4. The system of claim 1, further comprising:

a computer-readable program executed on a smart phone or tablet device, wherein the suggested glucagon dosage is calculated by the computer-readable program.

5. A medicine administration system, comprising:

a wearable glucose monitoring device;

a disposable and non-reusable insulin delivery device including;

an insulin cartridge comprising a plunger, a septum, and insulin;

a housing that retains the insulin cartridge; and

a drive system comprising a piston rod that is incrementally movable to apply a dispensing force to the plunger to dispense insulin through the septum;

a removable controller device including;

a controller housing that is removably attachable to the housing of the insulin delivery device;

a user interface comprising a display and one or more user-selectable buttons; and

a wireless communication device to receive glucose information from the wearable glucose monitoring device, the glucose information being indicative of a blood glucose level of the user; and

a glucagon dosage suggestion calculator that calculates a suggested glucagon dosage being at least partially dependent upon a glucose sensitivity value, a target blood glucose level, and the blood glucose level of the user; and

a glucagon injector pen device or syringe that is separate from the disposable and non-reusable insulin delivery device and the controller device.

6. The system of claim 5, wherein the glucagon dosage suggestion calculator comprises a computer readable program executed on a smart phone or tablet device.

7. The system of claim 5, wherein the glucagon dosage calculator is attached to the glucagon injector pen device or syringe.

8. The system of claim 5, wherein the glucagon dosage suggestion calculator is configured to interact with the glucagon injector pen device or syringe.

9. The system of claim 5, wherein the glucagon injector pen device or syringe is a glucagon injector pen in wireless communication with the removable controller device.

10. The system of claim 5, wherein the disposable and non-reusable insulin delivery device is an insulin pump.